A detailed history of Paladin Advisory Group, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Paladin Advisory Group, LLC holds 590 shares of LLY stock, worth $471,752. This represents 0.39% of its overall portfolio holdings.

Number of Shares
590
Previous 590 -0.0%
Holding current value
$471,752
Previous $534,000 2.25%
% of portfolio
0.39%
Previous 0.42%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 21, 2023

BUY
$310.63 - $364.82 $183,271 - $215,243
590 New
590 $202,000
Q1 2022

Apr 15, 2022

BUY
$234.69 - $291.66 $138,467 - $172,079
590 New
590 $172,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $760B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Paladin Advisory Group, LLC Portfolio

Follow Paladin Advisory Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paladin Advisory Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Paladin Advisory Group, LLC with notifications on news.